Barnaby Balmforth

Chief Executive Officer

Barnaby has more than 10 years’ experience in the leadership of genomic technology development. Prior to co-founding Biofidelity he was Chief Operating Officer and Board member at Base4 as well as leading the development of the company’s molecular biology. Barnaby holds a PhD from the University of Cambridge and a Masters from the University of Oxford.

Stephen Miller

Chief Commercial Officer

Stephen has more than 25 years’ experience in the leadership of high growth public and private diagnostics businesses in the US, including at Precipio Inc., BG Medicine, Thermo Fisher Scientific and Athena Diagnostics. He has a track record of successful commercialization of novel diagnostic technologies as well as securing high-multiple transactions.

Wendy J. Levin, MD, MS

Chief Medical Officer

Dr Levin is a US-trained oncologist and hematologist with over 15 years’ industry experience in translational medicine and drug development, leading clinical development and medical affairs as well as supporting business development. She has provided strategic support for pre-IPO start-ups and Fortune 500 companies, led health authority and regulatory interactions, executed clinical advisory boards, and provided clinical leadership for first-in-human studies to Phase 3 registration trials.

Robert Osborne

Chief Operating Officer

Robert has more than 15 years’ experience in the development and productization of genomic technologies, including more than a decade in product development at high growth start-ups. As SVP of Technology & Assay Development at Inivata he led flagship product development, from concept to CLIA/CAP-ready in less than 12 months, as well as the implementation of ISO standards and design control in line with FDA requirements.

Heiner Dreismann

Chairman

A veteran executive with over 35 years’ experience in high growth life science and healthcare businesses, Dr Dreismann was a pioneer in the early adoption of PCR technologies. Formerly the President and CEO of Roche Molecular Systems, he now serves on the boards of multiple healthcare companies in the US, Europe and Israel.

Barnaby Balmforth

Chief Executive Officer

Barnaby has more than 10 years’ experience in the leadership of genomic technology development. Prior to co-founding Biofidelity he was Chief Operating Officer and Board member at Base4 as well as leading the development of the company’s molecular biology. Barnaby holds a PhD from the University of Cambridge and a Masters from the University of Oxford.

Ciarán O’Leary

Director

Ciarán is a co-founder and General Partner at BlueYard Capital, a venture firm focusing on the decentralization of markets and the empowerment of humanity. Prior to co-founding BlueYard, Ciarán was a partner at VC firm Earlybird and before this was with the PE firm The Carlyle Group and M&A house Lazard.

Matthew Frohn

Director

As a Partner at Longwall Ventures, Matthew predominantly focuses on life science opportunities. He holds a D.Phil in Biochemistry from the University of Oxford and has pre-venture experience ranging from working in clinical pathology to virology with Zeneca to drug development with Neures.

Matt Franklin

Director

Matt’s distinguished career spans a wide range of innovative companies including senior leadership roles at Foundation Medicine, ArcherDX and Thrive Earlier Detection. Since 2015, the companies he has worked with have been acquired for a combined enterprise value of more than $8 billion. Currently, he serves as President and Chief Operating Officer of Akili, Inc. Matt holds a BA from Northwestern University and a MBA from the University of Michigan.

Mace Rothenberg, MD

Dr. Mace Rothenberg is former Chief Medical Officer of Pfizer, where he led their Worldwide Medical and Safety organization. Prior to his role as CMO, Dr. Rothenberg was Head of Clinical Development & Medical Affairs for Oncology at Pfizer from 2008 to 2016 and Chief Development Officer for Oncology from 2016 to 2018. His organization was responsible for the successful development and regulatory approval of 11 new cancer medicines, including IBRANCE® and XALKORI®. Prior to joining Pfizer, Dr. Rothenberg spent 25 years in academia where he focused on early-stage drug development, clinical trial design, and the evaluation of new cancer therapeutics.

Hesham A. Abdullah, MD, MS

Hesham A. Abdullah, MD, MS, is the Senior Vice President, Global Head Oncology, R&D at GSK, where he oversees end-to-end strategic development and delivery of GSK’s oncology clinical-stage portfolio. Dr. Abdullah has guided multiple oncology product approvals including Iressa®, Lynparza™, Tagrisso®, Imfinzi™, Calquence®, Lumoxiti™, Zejula®, Blenrep and Jemperli. Prior to leading oncology development at GSK, Dr. Abdullah rebuilt the Late-Stage Immuno-Oncology Development and Oncology Global Regulatory Sciences functions at AstraZeneca. He started his biopharmaceutical career in Global Regulatory Affairs at Amgen, before joining Medimmune in 2011 and AstraZeneca in 2013. He has over 16 years of oncology and immuno-oncology drug development experience.

Jerald Radich, MD

Dr. Jerald Radich is a Member of the Clinical Research Division, Director of the Molecular Oncology Lab and the Kurt Enslein Endowed Chair at the Fred Hutchinson Cancer Research Center. He is chair of the Leukemia Translational Medicine Committee of SWOG, and the inaugural Chair of the NCI and NIH Leukemia Steering Committee. Dr. Radich’s laboratory research centers on the molecular biology of response, resistance, and progression in adult and chronic leukemia. In addition, the CLIA Molecular Oncology Lab provides the molecular diagnostic support for many institutional, US Intergroup, international, and pharmaceutical trials. He was awarded Washington Global Health Alliance Partnership Award in 2019 for his lab’s work on diagnosing and monitoring CML in the developing world.

Lee Newcomer, MD